L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
EADV 2022 CASE REPORT: REDUCTION OF THE TOPICAL MINOXIDIL INTOLERANCE SIGNS THROUGH THE INCLUSION OF A DERMOCOSMETIC HAIR CARE ROUTINE IMPROVING THE SCALP MICRO-INFLAMMATION.
- 10min (reading time)
- Mar. 2023
- Supported by
INTRODUCTION
For many years, topical minoxidil solution has proven to be an effective treatment for androgenetic alopecia (AGA). However, some patients present scalp intolerance signs such as itching, scaling, exacerbation of seborrheic dermatitis and hair fiber drying which can affect the treatment adherence.The association of topical minoxidil with a dermocosmetic hair care routine which contains active ingredients with anti-inflammatory and vascular action, such as Aminexil® and Niacinamide, could help to reduce the scalp intolerance. Additionally, active ingredients intended to restore softness, strength and shine of the hair fiber could improve the adherence to AGA treatment.